ADMA Biologics Q1 revenue $56.9M (+96% YoY); first-time positive Adjusted EBITDA $2.5M

ADMA BIOLOGICS, INC.

2023-Q1 EPS reported -$0.03 revenue$56,913,534

Total revenues $56.9M, up 96% YoY; net loss narrowed to $6.8M from $25.0M.
First-time positive Adjusted EBITDA of $2.5M, ahead of forecast; FY2023 revenue guidance raised to >$220M.
Gross margin improved to 29.0% from 12.6%; legacy low-margin BIVIGAM inventory nearly depleted.
ASCENIV production scaled to 4,400L; expects margin expansion and plant capacity improvement.
Cash $69.2M; working capital $227.4M; strategic review ongoing with Morgan Stanley.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ADMA BIOLOGICS, INC. reported first quarter 2023 results: revenue $57 Million, net income Net Loss of $6.8 Million.

Period: first quarter 2023
Revenue: $57 Million
Net income: Net Loss of $6.8 Million
Result: reported results

Exact text from the filing

1Q2023 Total Revenues of $57 Million, a 96% Y-o-Y Increase 1Q2023 Net Loss of $6.8 Million, a 73% Y-o-Y Improvement

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ADMA BIOLOGICS, INC. reported FY2023 results: revenue $220 Million. Guidance raised.

Period: FY2023
Revenue: $220 Million
Guidance: raised
Result: guidance update

Exact text from the filing

FY2023 Total Revenue Now Expected to Exceed $220 Million, Increased from $210 Million

View on SEC.gov

Browse all earnings releases →

ADMA BIOLOGICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-23-023899

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.